Nevertheless, the data of these original safety trials have been the impetus and stimulus to conduct new trials evaluating the impact of SGLT2 inhibitors on heart failure outcomes in patients with established heart failure, both with diabetes mellitus and without diabetes mellitus. Here, SLC5A2 is linked to heart failure.